Drug attrition rates have increased in past years, resulting in growing costs 
for the pharmaceutical industry and consumers. The reasons for this include the 
lack of in vitro models that correlate with clinical results and poor 
preclinical toxicity screening assays. The in vitro production of human cardiac 
progenitor cells and cardiomyocytes from human pluripotent stem cells provides 
an amenable source of cells for applications in drug discovery, disease 
modeling, regenerative medicine, and cardiotoxicity screening. In addition, the 
ability to derive human-induced pluripotent stem cells from somatic tissues, 
combined with current high-throughput screening and pharmacogenomics, may help 
realize the use of these cells to fulfill the potential of personalized 
medicine. In this review, we discuss the use of pluripotent stem cell-derived 
cardiomyocytes for drug discovery and cardiotoxicity screening, as well as 
current hurdles that must be overcome for wider clinical applications of this 
promising approach.